— Know what they know.
Not Investment Advice

MNPR NASDAQ

Monopar Therapeutics Inc.
1W: +2.8% 1M: +17.6% 3M: +13.1% YTD: -5.0% 1Y: +69.9% 3Y: +1371.4% 5Y: +145.3%
$63.12
+0.44 (+0.70%)
After Hours: $58.75 (-4.37, -6.92%)
Weekly Expected Move ±9.6%
$48 $54 $59 $65 $71
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 60 · $422.8M mcap · 4M float · 4.58% daily turnover · Short 74% of daily vol

Balance Sheet Trends

Total Assets
$140.7B +233297.3% ▲
5Y CAGR: +508.5%
Total Liabilities
$2.9B +54905.5% ▲
5Y CAGR: +376.5%
Shareholders Equity
$137.8B +250328.1% ▲
5Y CAGR: +514.8%
Cash & Investments
$61.8B +102592.7% ▲
5Y CAGR: +417.0%
Total Debt
$155M +0.0% ▲
Net Debt
-$61.7B -134521.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$20M$8M$7M$46M$61.8B
Short-Term Investments$0$5M$0$14M$79M
Cash & ST Investments$20M$13M$7M$60M$61.8B
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$218K$46K$66K$79K$78.6B
Total Current Assets$21M$13M$7M$60M$140.5B
Property, Plant & Equip.$0$61K$13K$0$255M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$0$61K$13K$0$255M
Total Assets$21M$13M$7M$60M$140.7B
— Liabilities —
Accounts Payable$2M$3M$2M$2M$3M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$0$2.7B
Total Current Liabilities$2M$3M$2M$5M$2.7B
Long-Term Debt$0$0$0$0$155M
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$8K$0$0$155M
Total Liabilities$2M$3M$2M$5M$2.9B
— Equity —
Common Stock$13K$13K$15K$6K$7M
Retained Earnings-$41M-$52M-$60M-$76M-$89.5B
Accumulated OCI-$3K$9K-$14K$36K$131M
Total Stockholders Equity$19M$10M$6M$55M$137.8B
Total Liabilities & Equity$21M$13M$7M$60M$140.7B
— Key Metrics —
Total Debt$0$8K$0$0$155M
Net Debt-$20M-$8M-$7M-$46M-$61.7B
Total Investments$0$5M$0$14M$79M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms